
    
      EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between
      Tumor Associated Antigens and microbiome-derived peptides that will be administered in
      combination with nivolumab to generate preliminary safety and efficacy data in patients with
      Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
    
  